Stability-indicating HPLC assay and solution stability of a new diaziridinyl benzoquinone.
RH1, 3-methyl-6-hydroxymethyl-2,5-diaziridinyl-1,4-benzoquinone, is a NQO1 (NAD(P)H quinone oxidoreductase) directed anti-tumor agent. It is designed as a water soluble analog of MeDZQ (3,6-dimethyl-2,5-diaziridinyl-1,4-benzoquinone) and is a drug candidate for clinical evaluation. A HPLC assay has been developed for its analysis. The assay is sensitive (ldl<0.2 ng), precise (rsd<1%), linear (r(2)=0.9997), accurate (error<0.6%), and stability-indicating. Using the developed assay, aqueous stability of RH1 has been evaluated. Both aziridine rings in MeDZQ are known to be easily hydrolyzable in aqueous solutions, however, hydrolysis of the second aziridine ring in RH1 appears inhibited.
SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94205, USA. andrew.cheung@sri.com
A P
AP
Cheung
E
E
Struble
N
N
Nguyen
P
P
Liu
D001388:Aziridines / Q000737:chemistry*; D016227:Benzoquinones / Q000737:chemistry*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006868:Hydrolysis; D012680:Sensitivity and Specificity; D012996:Solutions; D013056:Spectrophotometry, Ultraviolet
C117776:2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone; D001388:Aziridines; D016227:Benzoquinones; D012996:Solutions